NEAT
Location:
Global, multi-site
Investigator:
Quince Therapeutics
Purpose:
To evaluate the effects of EryDex in patients with A-T. This is an international, multi-center, randomized, prospective, double-blind, placebo-controlled, Phase 3 study, designed to assess the effect of dexamethasone administered by intravenous (IV) infusion (once every 28 days) on neurological symptoms of patients with A-T.
Recruitment & More Information
To learn more about this study, please visit https://a-t-study.com/.